Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 million, with the deal expected to close by end of 2026. Leveraged ETFs also declined sharply amid the market downturn. These events highlight risks in biotech trials and strategic moves in medical tech sectors.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
On September 22, 2026, Ethereum (ETH) traded around $2,735, just below a key resistance zone between $2,750 and $2,800 where it has repeatedly bounced. Despite a recent upward trend, ETH failed to sustain above $2,800, signaling uncertainty in short-...
FirstService Residential has published its 2026 BENCHMARK report detailing operating costs, budgets, and trends in large master-planned and lifestyle communities across North America. The report highlights key budget areas like insurance, utilities, ...
The ALPS Medical Breakthroughs ETF (SBIO) focuses on late-stage biotech companies that have at least one Phase II or III clinical program and sufficient cash reserves to reduce dilution risk before key events. This strategy aims to capture upside fro...
McDonald’s is piloting a program to sell advertising space on its digital menu boards, displayed after customers place orders in drive-thrus and restaurants. The company aims to offer relevant content without disrupting the McDonald’s experience. Thi...
